Abstract Body

Background

DNA-encoded monoclonal antibodies (DMAbs) offer a potential long-acting, cold-chain–independent alternative to recombinant antibody delivery. Prior reports established durable in vivo expression through week 72. We now present extended follow-up to week 96, the longest reported for any DMAb clinical trial.

Methods

In this Phase 1, open-label, dose-escalation study (NCT05293249), healthy adults received intramuscular injections of plasmid DNA encoding two half-life–extended SARS-CoV-2 neutralizing antibodies (AZD5396 and AZD8076) delivered with CELLECTRA™ electroporation. Cohorts (0.25–2 mg per injection; 1–4 injection sites) were followed for safety, pharmacokinetics, immunogenicity, and functional activity. The primary endpoints were safety and serum antibody concentrations; exploratory endpoints included binding to SARS-CoV-2 spike variants, pseudovirus neutralization, and anti-drug antibody (ADA) detection.

Results

Forty-four participants received ≥1 dose. The product was well tolerated; no product-related serious adverse events occurred through week 96. The most common adverse events were transient injection-site pain and erythema. In 39 evaluable participants, in vivo–expressed DMAbs were quantifiable in 100% and persisted through week 96. Peak serum concentrations increased with multi-site administration, reaching >1 µg/mL in some individuals. Expression remained stable without decline between weeks 72 and 96. Binding to ancestral, Delta, and Omicron BA.2/BA.4/5 receptor-binding domains was sustained, and pseudovirus neutralization was demonstrated in all evaluable participants. No confirmed ADAs were detected in ~1,200 serum samples tested.

Conclusions

This study provides the first demonstration of safe, durable, and functional expression of DNA-encoded antibodies in humans through 96 weeks. The absence of ADA induction and sustained biologically relevant concentrations underscore the potential of DMAb technology. These findings lay the groundwork for a versatile, synthetic, non-viral gene therapy strategy with applications in infectious disease, chronic conditions, and beyond

Table or Figure